NIR-activated ADC overcomes dose-limiting adverse effects of conventional, toxin-loaded ADC systems
US-based contract manufacturing organisation Goodwin Biotechnology has entered into an agreement with San Diego-based start-up biotechnology company Aspyrian Therapeutics for the technology transfer, process development, scale-up and cGMP manufacturing of a novel Antibody Drug Conjugate (ADC) for use in Phase I clinical trials.
Aspyrian Therapeutics has secured an exclusive licence from the National Cancer Institute for a new ADC technology platform, Near-infrared Photoimmunotherapy (PIT). The technology is based on three components:
Upon administration of non-ionising NIR light, PIT induces rapid cell killing by localised disruption of cell membranes of only those cells targeted by the antibody conjugate. Importantly, unbound conjugates and free dye do not elicit any phototoxicity upon NIR irradiation. The combination of selective binding to surface antigens and organ-localised NIR activation permits highly efficacious disease-specific ablation, while sparing nearby healthy tissues and structures and thereby overcoming the dose-limiting adverse effects that have hindered the development of conventional, toxin-loaded ADC systems.
'We are pleased to have been selected to partner with Aspyrian Therapeutics for this leading edge ADC project,' said Dr SooYoung Lee, Chief Operating Officer at Goodwin Biotechnology. 'This important project is a testament to our experience and expertise in bioconjugation that has been developed and refined over more than a decade.
'This initiative has been led by Dr Muctarr Sesay, Vice President of Process Development, who is one of the pioneers in process development and cGMP manufacturing of many ADCs and biologic drug conjugates, which Goodwin has successfully manufactured for human clinical studies.'
'The technical expertise that Goodwin Biotechnology offers in the field of bioconjugation, coupled with the responsiveness and flexibility they exhibited during the selection process, made them the obvious choice,' noted Dr Miguel Garcia-Guzman, Chief Scientific Officer at Aspyrian Therapeutics. 'Our mission is to leverage the potential of the PIT platform by developing a pipeline of proprietary and partnered ADC products, and this collaboration represents a critical milestone in this endeavour.'